uns profit projections no dcf, page-10

Hey snork, feedback for you:

1. We would need to take out cash burn > Staff costs, R&D, facility etc etc.

2. Take out Sanofi's cut in any Access Fee's (70%) and 5% earnings from the prefill. Also I wouldn't think that an Access Fee could fetch more than the Exclusive Fee of $16m that Sanofi paid.

3. The capability to have the Select and Prefill ramping up at the same time is in question for me. The Griffin Report suggests not running in tandem but as replacement.

4. I remember (very fuzzy) that the 1ml for around 40m units would only really net $3m odd, need to check.


Just a few things to help progress this so that it can become a realistic and reliable thing to bounce off, great work and thanks snork. Also don't get me wrong I'm as bullish as anyone here, I'm sure you know that.